Chronic pain in Alzheimer's disease: Endocannabinoid system

Exp Neurol. 2023 Feb:360:114287. doi: 10.1016/j.expneurol.2022.114287. Epub 2022 Nov 29.

Abstract

Chronic pain, one of the most common reasons adults seek medical care, has been linked to restrictions in mobility and daily activities, dependence on opioids, anxiety, depression, sleep deprivation, and reduced quality of life. Alzheimer's disease (AD), a devastating neurodegenerative disorder (characterized by a progressive impairment of cognitive functions) in the elderly, is often co-morbid with chronic pain. AD is one of the most common neurodegenerative disorders in the aged population. The reported prevalence of chronic pain is 45.8% of the 50 million people with AD. As the population ages, the number of older people who experience AD and chronic pain will also increase. The current treatment options for chronic pain are limited, often ineffective, and have associated side effects. This review summarizes the role of the endocannabinoid system in pain, its potential role in chronic pain in AD, and addresses gaps and future directions.

Keywords: Aging; Alzheimer; Endocannabinoid; Pain.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Alzheimer Disease* / complications
  • Alzheimer Disease* / drug therapy
  • Alzheimer Disease* / epidemiology
  • Analgesics, Opioid
  • Chronic Pain* / epidemiology
  • Endocannabinoids / therapeutic use
  • Humans
  • Quality of Life

Substances

  • Endocannabinoids
  • Analgesics, Opioid